Home » Authors » Jennifer Boggs

Articles by Jennifer Boggs

GTC Is Raising $10M, Aiming For Transgenic Drug Approval

Jan. 25, 2005

By Jennifer Boggs

GTC Is Raising $10M, Aiming For Transgenic Drug Approval

Jan. 25, 2005

By Jennifer Boggs

Chelsea Joins With Ivory Capital, Goes Public Via Reverse Merger

Jan. 24, 2005

By Jennifer Boggs

Chelsea Joins With Ivory Capital, Goes Public Via Reverse Merger

Jan. 24, 2005

By Jennifer Boggs

Having IP, But No Compounds, Sention Signs Deal With Merck

Jan. 21, 2005

By Jennifer Boggs

Having IP, But No Compounds, Sention Signs Deal With Merck

Jan. 21, 2005

By Jennifer Boggs

Synta Files For $115M IPO; Proceeds To Push Pipeline

Jan. 20, 2005

By Jennifer Boggs

Synta Files For $115M IPO; Proceeds To Push Pipeline

Jan. 20, 2005

By Jennifer Boggs

Compound Therapeutics Gets $15.5M In Expanded Financing

Jan. 19, 2005

By Jennifer Boggs

Compound Therapeutics Gets $15.5M In Expanded Financing

Jan. 19, 2005

By Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 26, 2026.
Sangamo presents primate data for prion suppressor ST-506
BioWorld Science
Sangamo Therapeutics Inc. discussed gene regulation approaches for neurodegenerative diseases when presenting findings on their clinical candidate ST-506 for the...
TREM2 agonists detailed in Pfizer patent
BioWorld Science
Pfizer Inc. has reported new triggering receptor expressed on myeloid cells 2 (TREM2) agonists potentially useful for the treatment of neurodegeneration.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 26, 2026
Dual-targeting, rapamycin-enhanced CAR T for multiple myeloma
BioWorld Science
Umoja Biopharma Inc. performed preclinical studies to evaluate the antitumor activity of UB-VV500, an off-the-shell lentiviral vector CAR T-cell product. It is...